Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.

Chengdu-based Biokin has just signed a $8.4bn licensing deal with BMS for an ADC asset, while Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in China. Meanwhile, BlissBio has released new clinical data for its HER2-targeting ADC and shares in WuXi Biologics have plummeted following its latest business updates.

Numerous companies are evaluating CXCR4 antagonists in early-stage clinical studies for their potential in stem cell transplantation, acute myeloid leukemia and other disorders, and BioLineRx's lead compound appears to be a frontrunner in the race to market.

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.